Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 59 entries
Sorted by: Best Match Show Resources per page
Setting the benchmark.

The Journal of thoracic and cardiovascular surgery

Sundt TM.
PMID: 27085614
J Thorac Cardiovasc Surg. 2016 May;151(5):1339. doi: 10.1016/j.jtcvs.2016.03.005. Epub 2016 Mar 10.

No abstract available.

Cite
Sundt TM. Setting the benchmark. J Thorac Cardiovasc Surg. 2016;151(5):1339doi: 10.1016/j.jtcvs.2016.03.005.
Sundt, T. M. (2016). Setting the benchmark. The Journal of thoracic and cardiovascular surgery, 151(5), 1339. https://doi.org/10.1016/j.jtcvs.2016.03.005
Sundt, Thoralf M. "Setting the benchmark." The Journal of thoracic and cardiovascular surgery vol. 151,5 (2016): 1339. doi: https://doi.org/10.1016/j.jtcvs.2016.03.005
Sundt TM. Setting the benchmark. J Thorac Cardiovasc Surg. 2016 May;151(5):1339. doi: 10.1016/j.jtcvs.2016.03.005. Epub 2016 Mar 10. PMID: 27085614.
Copy Download .nbib Format: NLM
Analysis of COVID-19 vaccines: Types, thoughts, and application.

Journal of clinical laboratory analysis

Han X, Xu P, Ye Q.
PMID: 34396586
J Clin Lab Anal. 2021 Sep;35(9):e23937. doi: 10.1002/jcla.23937. Epub 2021 Aug 15.

OBJECTIVE: To deal with COVID-19, various countries have made many efforts, including the research and development of vaccines. The purpose of this manuscript was to summarize the development, application, and problems of COVID-19 vaccines.METHODS: This article reviewed the existing...

Cite
Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937doi: 10.1002/jcla.23937.
Han, X., Xu, P., & Ye, Q. (2021). Analysis of COVID-19 vaccines: Types, thoughts, and application. Journal of clinical laboratory analysis, 35(9), e23937. https://doi.org/10.1002/jcla.23937
Han, Xiucui, et al. "Analysis of COVID-19 vaccines: Types, thoughts, and application." Journal of clinical laboratory analysis vol. 35,9 (2021): e23937. doi: https://doi.org/10.1002/jcla.23937
Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021 Sep;35(9):e23937. doi: 10.1002/jcla.23937. Epub 2021 Aug 15. PMID: 34396586; PMCID: PMC8418485.
Copy Download .nbib Format: NLM
Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.

Clinical therapeutics

Tibaldi JM.
PMID: 22030443
Clin Ther. 2011 Nov;33(11):1630-42. doi: 10.1016/j.clinthera.2011.09.019. Epub 2011 Oct 26.

BACKGROUND: As the diabetes epidemic expands, health care providers need more options to achieve glycemic control. Insulin analogue premixes provide basal and prandial insulin with 1 injection.OBJECTIVES: The aim of this review was to provide an overview of the...

Cite
Tibaldi JM. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther. 2011;33(11):1630-42doi: 10.1016/j.clinthera.2011.09.019.
Tibaldi, J. M. (2011). Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clinical therapeutics, 33(11), 1630-42. https://doi.org/10.1016/j.clinthera.2011.09.019
Tibaldi, Joseph M. "Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes." Clinical therapeutics vol. 33,11 (2011): 1630-42. doi: https://doi.org/10.1016/j.clinthera.2011.09.019
Tibaldi JM. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther. 2011 Nov;33(11):1630-42. doi: 10.1016/j.clinthera.2011.09.019. Epub 2011 Oct 26. PMID: 22030443.
Copy Download .nbib Format: NLM
Pediatric dose selection.

Clinical pharmacology and therapeutics

Abernethy DR, Burckart GJ.
PMID: 20160747
Clin Pharmacol Ther. 2010 Mar;87(3):270-1. doi: 10.1038/clpt.2009.292.

Selection of a drug dose in pediatrics is generally based on no or incomplete pharmacokinetic data. Traditionally, allometric, or scaling, techniques have been used; however, they have inherent limitations and may not make optimal use of the drug-specific clinical...

Cite
Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87(3):270-1doi: 10.1038/clpt.2009.292.
Abernethy, D. R., & Burckart, G. J. (2010). Pediatric dose selection. Clinical pharmacology and therapeutics, 87(3), 270-1. https://doi.org/10.1038/clpt.2009.292
Abernethy, D R, and Burckart, G J. "Pediatric dose selection." Clinical pharmacology and therapeutics vol. 87,3 (2010): 270-1. doi: https://doi.org/10.1038/clpt.2009.292
Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010 Mar;87(3):270-1. doi: 10.1038/clpt.2009.292. PMID: 20160747.
Copy Download .nbib Format: NLM
[Application of pharmacometrics in personalized therapy in children].

Zhonghua er ke za zhi = Chinese journal of pediatrics

Hao G, Zheng Y, Evelyne JA, Zhao W.
PMID: 26757963
Zhonghua Er Ke Za Zhi. 2015 Sep;53(9):647-9.

No abstract available.

Cite
Hao G, Zheng Y, Evelyne JA, et al. [Application of pharmacometrics in personalized therapy in children]. Zhonghua Er Ke Za Zhi. 2015;53(9):647-9
Hao, G., Zheng, Y., Evelyne, J. A., & Zhao, W. (2015). [Application of pharmacometrics in personalized therapy in children]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 53(9), 647-9.
Hao, Guoxiang, et al. "[Application of pharmacometrics in personalized therapy in children]." Zhonghua er ke za zhi = Chinese journal of pediatrics vol. 53,9 (2015): 647-9.
Hao G, Zheng Y, Evelyne JA, Zhao W. [Application of pharmacometrics in personalized therapy in children]. Zhonghua Er Ke Za Zhi. 2015 Sep;53(9):647-9. Chinese. PMID: 26757963.
Copy Download .nbib Format: NLM
Modeling for regulatory purposes (risk and safety assessment).

Methods in molecular biology (Clifton, N.J.)

El-Masri H.
PMID: 23086847
Methods Mol Biol. 2013;930:297-303. doi: 10.1007/978-1-62703-059-5_13.

Chemicals provide many key building blocks that are converted into end-use products or used in industrial processes to make products that benefit society. Ensuring the safety of chemicals and their associated products is a key regulatory mission. Current processes...

Cite
El-Masri H. Modeling for regulatory purposes (risk and safety assessment). Methods Mol Biol. 2013;930:297-303doi: 10.1007/978-1-62703-059-5_13.
El-Masri, H. (2013). Modeling for regulatory purposes (risk and safety assessment). Methods in molecular biology (Clifton, N.J.), 930297-303. https://doi.org/10.1007/978-1-62703-059-5_13
El-Masri, Hisham. "Modeling for regulatory purposes (risk and safety assessment)." Methods in molecular biology (Clifton, N.J.) vol. 930 (2013): 297-303. doi: https://doi.org/10.1007/978-1-62703-059-5_13
El-Masri H. Modeling for regulatory purposes (risk and safety assessment). Methods Mol Biol. 2013;930:297-303. doi: 10.1007/978-1-62703-059-5_13. PMID: 23086847.
Copy Download .nbib Format: NLM
Evidence-based drug treatment for special patient populations through model-based approaches.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ.
PMID: 28502674
Eur J Pharm Sci. 2017 Nov 15;109:S22-S26. doi: 10.1016/j.ejps.2017.05.022. Epub 2017 May 11.

The majority of marketed drugs remain understudied in some patient populations such as pregnant women, paediatrics, the obese, the critically-ill, and the elderly. As a consequence, currently used dosing regimens may not assure optimal efficacy or minimal toxicity in...

Cite
Krekels EHJ, van Hasselt JGC, van den Anker JN, et al. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109:S22-S26doi: 10.1016/j.ejps.2017.05.022.
Krekels, E. H. J., van Hasselt, J. G. C., van den Anker, J. N., Allegaert, K., Tibboel, D., & Knibbe, C. A. J. (2017). Evidence-based drug treatment for special patient populations through model-based approaches. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 109S22-S26. https://doi.org/10.1016/j.ejps.2017.05.022
Krekels, Elke H J, et al. "Evidence-based drug treatment for special patient populations through model-based approaches." European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences vol. 109 (2017): S22-S26. doi: https://doi.org/10.1016/j.ejps.2017.05.022
Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017 Nov 15;109:S22-S26. doi: 10.1016/j.ejps.2017.05.022. Epub 2017 May 11. PMID: 28502674.
Copy Download .nbib Format: NLM
Environmental hormesis and its fundamental biological basis: Rewriting the history of toxicology.

Environmental research

Agathokleous E, Kitao M, Calabrese EJ.
PMID: 29734028
Environ Res. 2018 Aug;165:274-278. doi: 10.1016/j.envres.2018.04.034. Epub 2018 May 07.

It has long been debated whether a little stress may be "good" for you. Extensive evidence has now sufficiently accumulated demonstrating that low doses of a vast range of chemical and physical agents induce protective/beneficial effects while the opposite...

Cite
Agathokleous E, Kitao M, Calabrese EJ. Environmental hormesis and its fundamental biological basis: Rewriting the history of toxicology. Environ Res. 2018;165:274-278doi: 10.1016/j.envres.2018.04.034.
Agathokleous, E., Kitao, M., & Calabrese, E. J. (2018). Environmental hormesis and its fundamental biological basis: Rewriting the history of toxicology. Environmental research, 165274-278. https://doi.org/10.1016/j.envres.2018.04.034
Agathokleous, Evgenios, et al. "Environmental hormesis and its fundamental biological basis: Rewriting the history of toxicology." Environmental research vol. 165 (2018): 274-278. doi: https://doi.org/10.1016/j.envres.2018.04.034
Agathokleous E, Kitao M, Calabrese EJ. Environmental hormesis and its fundamental biological basis: Rewriting the history of toxicology. Environ Res. 2018 Aug;165:274-278. doi: 10.1016/j.envres.2018.04.034. Epub 2018 May 07. PMID: 29734028.
Copy Download .nbib Format: NLM
A generally useful modification of ALLFIT that facilitates the fitting of null equations to dose-response curves.

Trends in pharmacological sciences

Mackay D.
PMID: 3245085
Trends Pharmacol Sci. 1988 Apr;9(4):121-2. doi: 10.1016/0165-6147(88)90189-7.

No abstract available.

Cite
Mackay D. A generally useful modification of ALLFIT that facilitates the fitting of null equations to dose-response curves. Trends Pharmacol Sci. 1988;9(4):121-2doi: 10.1016/0165-6147(88)90189-7.
Mackay, D. (1988). A generally useful modification of ALLFIT that facilitates the fitting of null equations to dose-response curves. Trends in pharmacological sciences, 9(4), 121-2. https://doi.org/10.1016/0165-6147(88)90189-7
Mackay, D. "A generally useful modification of ALLFIT that facilitates the fitting of null equations to dose-response curves." Trends in pharmacological sciences vol. 9,4 (1988): 121-2. doi: https://doi.org/10.1016/0165-6147(88)90189-7
Mackay D. A generally useful modification of ALLFIT that facilitates the fitting of null equations to dose-response curves. Trends Pharmacol Sci. 1988 Apr;9(4):121-2. doi: 10.1016/0165-6147(88)90189-7. PMID: 3245085.
Copy Download .nbib Format: NLM
Linking Exome Sequencing Data with Drug Response Aberrations.

Studies in health technology and informatics

Kyriakidis K, Charalampidou A, Natsiavas P, Vizirianakis IS, Malousi A.
PMID: 31438372
Stud Health Technol Inform. 2019 Aug 21;264:1845-1846. doi: 10.3233/SHTI190677.

Next-generation sequencing has prompted the development of numerous -omics applications. Along with experimental procedures, various computational pipelines became available to address the inherent complexities concerning the volume and quality of data. These pipelines are effective and routinely applied; however,...

Cite
Kyriakidis K, Charalampidou A, Natsiavas P, et al. Linking Exome Sequencing Data with Drug Response Aberrations. Stud Health Technol Inform. 2019;264:1845-1846doi: 10.3233/SHTI190677.
Kyriakidis, K., Charalampidou, A., Natsiavas, P., Vizirianakis, I. S., & Malousi, A. (2019). Linking Exome Sequencing Data with Drug Response Aberrations. Studies in health technology and informatics, 2641845-1846. https://doi.org/10.3233/SHTI190677
Kyriakidis, Konstantinos, et al. "Linking Exome Sequencing Data with Drug Response Aberrations." Studies in health technology and informatics vol. 264 (2019): 1845-1846. doi: https://doi.org/10.3233/SHTI190677
Kyriakidis K, Charalampidou A, Natsiavas P, Vizirianakis IS, Malousi A. Linking Exome Sequencing Data with Drug Response Aberrations. Stud Health Technol Inform. 2019 Aug 21;264:1845-1846. doi: 10.3233/SHTI190677. PMID: 31438372.
Copy Download .nbib Format: NLM
Solving the problem of dose optimization of children's medicines.

Expert review of clinical pharmacology

McWilliam SJ, Hawcutt DB.
PMID: 29355041
Expert Rev Clin Pharmacol. 2018 Mar;11(3):205-208. doi: 10.1080/17512433.2018.1431528. Epub 2018 Jan 30.

No abstract available.

Cite
McWilliam SJ, Hawcutt DB. Solving the problem of dose optimization of children's medicines. Expert Rev Clin Pharmacol. 2018;11(3):205-208doi: 10.1080/17512433.2018.1431528.
McWilliam, S. J., & Hawcutt, D. B. (2018). Solving the problem of dose optimization of children's medicines. Expert review of clinical pharmacology, 11(3), 205-208. https://doi.org/10.1080/17512433.2018.1431528
McWilliam, Stephen J, and Hawcutt, Daniel B. "Solving the problem of dose optimization of children's medicines." Expert review of clinical pharmacology vol. 11,3 (2018): 205-208. doi: https://doi.org/10.1080/17512433.2018.1431528
McWilliam SJ, Hawcutt DB. Solving the problem of dose optimization of children's medicines. Expert Rev Clin Pharmacol. 2018 Mar;11(3):205-208. doi: 10.1080/17512433.2018.1431528. Epub 2018 Jan 30. PMID: 29355041.
Copy Download .nbib Format: NLM
[Bonferroni-Holm sequential test procedure].

Zeitschrift fur Gastroenterologie

Sonnenberg A.
PMID: 4090570
Z Gastroenterol. 1985 Dec;23(12):703-4.

No abstract available.

Cite
Sonnenberg A. Die sequentielle Testprozedur nach Bonferroni-Holm. [Bonferroni-Holm sequential test procedure]. Z Gastroenterol. 1985;23(12):703-4
Sonnenberg, A. (1985). Die sequentielle Testprozedur nach Bonferroni-Holm. [Bonferroni-Holm sequential test procedure]. Zeitschrift fur Gastroenterologie, 23(12), 703-4.
Sonnenberg, A. "Die sequentielle Testprozedur nach Bonferroni-Holm." [Bonferroni-Holm sequential test procedure]. Zeitschrift fur Gastroenterologie vol. 23,12 (1985): 703-4.
Sonnenberg A. Die sequentielle Testprozedur nach Bonferroni-Holm. [Bonferroni-Holm sequential test procedure]. Z Gastroenterol. 1985 Dec;23(12):703-4. German. PMID: 4090570.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 59 entries